Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16480419 | 0.79 | MAPT (0.52) | MAPTALDH1A1KMT2ASRD5A1SRD5A2 | |
| SCHEMBL9891824 | 0.78 | MAPT (0.53) | MAPTALDH1A1KMT2ASRD5A1SRD5A2 | |
| SCHEMBL9893050 | 0.75 | MAPT (0.47) | MAPTALDH1A1KMT2ASRD5A1SRD5A2 | |
| SCHEMBL28790486 | 0.67 | MAPT (0.69) | MAPTALDH1A1KMT2ASRD5A1 | |
| SCHEMBL15448162 | 0.66 | MAPT (0.72) | MAPTALDH1A1KMT2A | |
| SCHEMBL24775523 | 0.65 | LMNA (0.44) | MAPTKMT2ALMNA | |
| SCHEMBL24421824 | 0.64 | MAPT (0.87) | MAPTALDH1A1KMT2ASRD5A1LMNA | |
| SCHEMBL9891859 | 0.64 | NUDT1 (0.36) | ALDH1A1LMNA | |
| SCHEMBL22606166 | 0.63 | ALDH1A1 (0.83) | MAPTALDH1A1KMT2ALMNA | |
| SCHEMBL16906206 | 0.62 | MAPT (0.74) | MAPTALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | MAPT 4057/4885ALDH1A1 3279/4885KMT2A 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.